Efavirenz / emtricitabine / tenofovir disoproxil (as fumarate) (Atripla®) for the treatment of HIV-1 infection in adults
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000419
English
Authors' recommendations:
Efavirenz / emtricitabine / tenofovir disoproxil (as fumarate) (Atripla®) is recommended as an option for use within NHS Wales for the treatment of HIV-1 infection in adults with virological suppression to HIV-1 RNA levels of <50 copies/ml on their current combination antiviral therapy for more than three months and in accordance with current BHIVA guidance.
AWMSG is of the opinion that efavirenz / emtricitabine / tenofovir disoproxil (as fumarate) (Atripla®) is not suitable for shared care within NHS Wales.
Details
Project Status:
Completed
Year Published:
2009
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=116673&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Adenine
- Deoxycytidine
- Oxazines
- Benzoxazines
- Drug Therapy, Combination
- HIV Infections
- Adult
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.